David: Certainly agree with what you say. Holding the company together with financial bandaids on a yearly basis is not, to say the least, optimal. But this is my point--with new people will come new ideas, and hopefully, new and rational business plans. I'm all in favor of a rational business plan, but just who in managment could have put it together? But now just who the company selects for the management positions will be absolutely critical. In my experience, despite the remonstrances of another poster, the biotech arena is by far and large a younger person's game, and by that I mean age 40's and 50's. Start up biotech companies are not established widgit-producing businesses. Much has to be done on the fly, and that requires an expenditure of human energy that tends to diminish as people age. Of course, if Warren Buffett wants to take CYGX and be the next CEO, I would have no objection other than the fact that there is no evidence that he understands their science, though I'm sure that the those he'd hire would. But, Mr. Buffett is one unusual individual, and I suspect he'd be a bit pricey for us.
News 
Market Data 
Discover 
